RESUMO
Objective: The advancement of neuroimaging and genetic research has revealed the presence of morphological abnormalities and numerous risk genes, along with their associations. We aimed to estimate magnetic resonance imaging-derived cortical thickness across multiple brain regions. Methods: The cortical thickness of 129 schizophrenia patients, 42 of their unaffected siblings, and 112 healthy controls was measured and the candidate genes were sequenced. Comparisons were made of cortical thickness (including 68 regions of the Desikan-Killiany Atlas) and genetic variants (in 108 risk genes for schizophrenia) among the three groups, and correlation analyses were performed regarding cortical thickness, clinical symptoms, cognitive tests (such as the N-back task and the logical memory test), and genetic variants. Results: Schizophrenia patients had significantly thinner bilateral frontal, temporal, and parietal gyri than healthy controls and unaffected siblings. Association analyses in target genes showed that four single nucleotide variants (SNVs) were significantly associated with schizophrenia, including thioredoxin-related transmembrane protein 2-catenin, cadherin-associated protein, delta 1 (SNV20673) (positive false discovery rate [PFDR] = 0.008) and centromere protein M (rs35542507, rs41277477, rs73165153) (PFDR = 0.030). Additionally, cortical thickness in the right pars triangularis was lower in carriers of the SNV20673 variant than in non-carriers (PFDR = 0.048). Finally, a positive correlation was found between right pars triangularis cortical thickness and logical memory in schizophrenia patients (r = 0.199, p = 0.032). Conclusions: This study identified regional morphological abnormalities in schizophrenia, including the right homologue of Broca's area, which was associated with a risk variant that affected delta-1 catenin and logical memory. These findings suggest a potential association between candidate gene loci, cortical thickness, and schizophrenia.
RESUMO
ABSTRACT Objective Increasing evidence demonstrates that oxidative stress and inflammatory are involved in amyloid β (Aβ)-induced memory impairments. Ursolic acid (UA), a triterpenoid compound, has potent anti-inflammatory and antioxidant activities. However, it remains unclear whether UA attenuates Aβ-induced neurotoxicity. Method The aggregated Aβ25-35 was intracerebroventricularly administered to mice. Results We found that UA significantly reversed the Aβ25-35-induced learning and memory deficits. Our results indicated that one of the potential mechanisms of the neuroprotective effect was attenuating the Aβ25-35-induced accumulation of malondialdehyde (MDA) and depletion of glutathione (GSH) in the hippocampus. Furthermore, UA significantly suppressed the upregulation of IL-1β, IL-6, and tumor necrosis-α factor levels in the hippocampus of Aβ25-35-treated mice. Conclusion These findings suggest that UA prevents memory impairment through amelioration of oxidative stress, inflammatory response and may offer a novel therapeutic strategy for the treatment of Alzheimer’s disease.
RESUMO Objetivo Há evidências crescentes de que o estresse oxidativo e a inflamação estão envolvidos na perda de memória induzida pelo peptídeo beta-amilóide (βA). O ácido ursólico (AU), um composto triterpenóide, apresenta atividades anti-inflamatórias e antioxidantes potentes. Entretanto, não se sabe ainda se o AU atenua a neurotoxicidade induzida pelo βA. Método O agregado βA 25-35 foi administrado aos ratos por via intracerebroventricular. Resultados Observou-se que o AU reverteu significativamente os déficits de aprendizado e de memória induzidos pelo βA 25-35. Portanto, um dos potenciais mecanismos do efeito neuroprotetor seria a atenuação do acúmulo de malondialdeído e a depleção de glutationa no hipocampo induzidos pelo βA 25-35. Além disso, o AU suprimiu significativamente a supra regulação dos níveis de IL-1β, IL-6 e do fator de necrose tumoral α no hipocampo dos ratos tratados com βA 25-35. Conclusão Esses achados sugerem que o AU previne a perda de memória através da melhora do estresse oxidativo e da resposta inflamatória, podendoproporcionar uma nova estratégia terapêutica para o tratamento da doença de Alzheimer.